Seeking Alpha

Oncothyreon -9.4% AH; tecemotide study fails to meet endpoints

  • Merck has informed Oncothyreon (NASDAQ:ONTY) a randomized Phase 1/2 study of its tecemotide immunotherapy in Japanese Stage III non-small cell lung cancer patients "did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen in any of the secondary endpoints (progression free survival, time to progression or time to failure)."
  • Merck has advised Oncothyreon it will "recommend that the investigational treatment in the study be discontinued and that no recruitment of Japanese patients into the Phase 3 program of tecemotide will take place."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector